According to the GH electronic database, the prevalence of FGFR2/3 fusions in liquid biopsy specimens from patients with aNSCLC was 0.28%, whereas the analysis of TASMC electronic database demonstrated FGFR fusions prevalence in tumor tissue specimens of 0.62%. Here, FGFR2 is linked to neoplasm.